Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 10/2017

17.08.2017 | 2017 SSAT Poster Presentation

Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer

verfasst von: Naruhiko Ikoma, Mariela Blum, Jeannelyn S. Estrella, Xuemei Wang, Keith F. Fournier, Paul F. Mansfield, Jaffer A. Ajani, Brian D. Badgwell

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

The Japanese Classification of Gastric Carcinoma includes the left gastric artery (#7) lymph nodes (LNs) in the recommended extent of D1 LN dissection, but this recommendation has not been validated in western institutions.

Methods

We reviewed data from a prospectively maintained database of gastric cancer patients who underwent resection at our academic cancer center and had a separate pathologic assessment of #7 LN in 2005–2016. Risk factors for #7 LN metastases and overall survival were examined by uni- and multivariable analyses.

Results

We identified 173 patients; 114 (66%) were treated with preoperative therapy, most commonly with chemoradiation therapy (47%, 81/173). We identified 22 patients (13%) who had #7 LN metastases, which accounted for 35% (22/63) of node-positive patients. No preoperative factors were associated with #7 LN metastases by univariable analyses. Patients with #7 metastases were not associated with shorter overall survival after adjustment by nodal stage (hazard ratio 1.49, 95% confidence interval 0.67–3.32; p = 0.33).

Conclusion

Metastasis to #7 LN station was common in gastric cancer, but the survival impact was not significant after adjustment by nodal stage. We conclude that #7 LNs should be routinely dissected in gastric cancer patients, and this station should be included within the extent of D1 LN dissection.
Literatur
1.
Zurück zum Zitat Sano T, Coit DG, Kim HH, Roviello F, Kassab P, Wittekind C et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2017;20(2):217–25. doi:10.1007/s10120-016-0601-9.CrossRef Sano T, Coit DG, Kim HH, Roviello F, Kassab P, Wittekind C et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2017;20(2):217–25. doi:10.​1007/​s10120-016-0601-9.CrossRef
3.
Zurück zum Zitat Fleming ID CJ, Henson DE, Manual for Staging of Cancer (5th ed.). American Joint Committee on Cancer (AJCC). Philadelphia: Lippincott; 1997. Fleming ID CJ, Henson DE, Manual for Staging of Cancer (5th ed.). American Joint Committee on Cancer (AJCC). Philadelphia: Lippincott; 1997.
4.
Zurück zum Zitat Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2011;14(2):101–12. doi:10.1007/s10120-011-0041-5.CrossRef Japanese Gastric Cancer A. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2011;14(2):101–12. doi:10.​1007/​s10120-011-0041-5.CrossRef
5.
Zurück zum Zitat Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Annals of Surgery. 2000;232(3):362–71.CrossRefPubMedPubMedCentral Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Annals of Surgery. 2000;232(3):362–71.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Fujii K, Isozaki H, Okajima K, Nomura E, Niki M, Sako S et al. Clinical evaluation of lymph node metastasis in gastric cancer defined by the fifth edition of the TNM classification in comparison with the Japanese system. The British Journal of Surgery. 1999;86(5):685–9. doi:10.1046/j.1365-2168.1999.01115.x.CrossRefPubMed Fujii K, Isozaki H, Okajima K, Nomura E, Niki M, Sako S et al. Clinical evaluation of lymph node metastasis in gastric cancer defined by the fifth edition of the TNM classification in comparison with the Japanese system. The British Journal of Surgery. 1999;86(5):685–9. doi:10.​1046/​j.​1365-2168.​1999.​01115.​x.CrossRefPubMed
9.
Zurück zum Zitat Ichikura T, Tomimatsu S, Uefuji K, Kimura M, Uchida T, Morita D et al. Evaluation of the New American Joint Committee on Cancer/International Union against cancer classification of lymph node metastasis from gastric carcinoma in comparison with the Japanese classification. Cancer. 1999;86(4):553–8.CrossRefPubMed Ichikura T, Tomimatsu S, Uefuji K, Kimura M, Uchida T, Morita D et al. Evaluation of the New American Joint Committee on Cancer/International Union against cancer classification of lymph node metastasis from gastric carcinoma in comparison with the Japanese classification. Cancer. 1999;86(4):553–8.CrossRefPubMed
10.
Zurück zum Zitat Ikoma N EJ, Blum MA, Chen HC, Wang X, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. Lymph node metastasis in gastric cancer: Location of positive station to predict survival after preoperative therapy. Gastrointestinal Cancers Symposium; San Francisco: Journal of Clinical Oncology 35, 2017 (suppl 4S; abstract 166) 166. Ikoma N EJ, Blum MA, Chen HC, Wang X, Fournier KF, Mansfield PF, Ajani JA, Badgwell BD. Lymph node metastasis in gastric cancer: Location of positive station to predict survival after preoperative therapy. Gastrointestinal Cancers Symposium; San Francisco: Journal of Clinical Oncology 35, 2017 (suppl 4S; abstract 166) 166.
12.
Zurück zum Zitat Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2017;20(1):1–19. doi: 10.1007/s10120-016-0622-4.CrossRef Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer: Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2017;20(1):1–19. doi: 10.​1007/​s10120-016-0622-4.CrossRef
13.
Zurück zum Zitat Badgwell B, Ajani J, Blum M, Ho L, Fournier K, Chiang YJ et al. Postoperative morbidity and mortality rates are not increased for patients with gastric and gastroesophageal cancer who undergo preoperative chemoradiation therapy. Annals of Surgical Oncology. 2016;23(1):156–62. doi:10.1245/s10434-015-4643-8.CrossRefPubMed Badgwell B, Ajani J, Blum M, Ho L, Fournier K, Chiang YJ et al. Postoperative morbidity and mortality rates are not increased for patients with gastric and gastroesophageal cancer who undergo preoperative chemoradiation therapy. Annals of Surgical Oncology. 2016;23(1):156–62. doi:10.​1245/​s10434-015-4643-8.CrossRefPubMed
14.
Zurück zum Zitat Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A et al. Predictors of survival in patients with resectable gastric cancer treated with preoperative chemoradiation therapy and gastrectomy. Journal of the American College of Surgeons. 2015;221(1):83–90. doi:10.1016/j.jamcollsurg.2015.04.004.CrossRefPubMed Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A et al. Predictors of survival in patients with resectable gastric cancer treated with preoperative chemoradiation therapy and gastrectomy. Journal of the American College of Surgeons. 2015;221(1):83–90. doi:10.​1016/​j.​jamcollsurg.​2015.​04.​004.CrossRefPubMed
15.
Zurück zum Zitat Badgwell B, Blum M, Elimova E, Estrella J, Chiang YJ, Das P et al. Frequency of resection after preoperative chemotherapy or chemoradiotherapy for gastric adenocarcinoma. Annals of Surgical Oncology. 2016;23(6):1948–55. doi:10.1245/s10434-016-5112-8.CrossRefPubMed Badgwell B, Blum M, Elimova E, Estrella J, Chiang YJ, Das P et al. Frequency of resection after preoperative chemotherapy or chemoradiotherapy for gastric adenocarcinoma. Annals of Surgical Oncology. 2016;23(6):1948–55. doi:10.​1245/​s10434-016-5112-8.CrossRefPubMed
16.
Zurück zum Zitat Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2016;14(10):1286–312.CrossRefPubMed Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P et al. Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2016;14(10):1286–312.CrossRefPubMed
17.
18.
Zurück zum Zitat Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. The British Journal of Surgery. 2014;101(2):23–31. doi:10.1002/bjs.9345.CrossRefPubMed Degiuli M, Sasako M, Ponti A, Vendrame A, Tomatis M, Mazza C et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. The British Journal of Surgery. 2014;101(2):23–31. doi:10.​1002/​bjs.​9345.CrossRefPubMed
19.
Zurück zum Zitat Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. The British Journal of Surgery. 1995;82(3):346–51.CrossRefPubMed Sasako M, McCulloch P, Kinoshita T, Maruyama K. New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. The British Journal of Surgery. 1995;82(3):346–51.CrossRefPubMed
20.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England Journal of Medicine. 2006;355(1):11–20. doi:10.1056/NEJMoa055531.CrossRefPubMed Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. The New England Journal of Medicine. 2006;355(1):11–20. doi:10.​1056/​NEJMoa055531.CrossRefPubMed
21.
Zurück zum Zitat Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29(13):1715–21. doi:10.1200/JCO.2010.33.0597.CrossRef Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2011;29(13):1715–21. doi:10.​1200/​JCO.​2010.​33.​0597.CrossRef
22.
Zurück zum Zitat Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010;28(35):5210–8. doi:10.1200/JCO.2009.26.6114.CrossRef Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010;28(35):5210–8. doi:10.​1200/​JCO.​2009.​26.​6114.CrossRef
23.
Zurück zum Zitat Greenleaf EK, Hollenbeak CS, Wong J. Trends in the use and impact of neoadjuvant chemotherapy on perioperative outcomes for resected gastric cancer: evidence from the American College of Surgeons National Cancer Database. Surgery. 2016;159(4):1099–112. doi:10.1016/j.surg.2015.11.004.CrossRefPubMed Greenleaf EK, Hollenbeak CS, Wong J. Trends in the use and impact of neoadjuvant chemotherapy on perioperative outcomes for resected gastric cancer: evidence from the American College of Surgeons National Cancer Database. Surgery. 2016;159(4):1099–112. doi:10.​1016/​j.​surg.​2015.​11.​004.CrossRefPubMed
24.
Zurück zum Zitat Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. The British Journal of Surgery. 2014;101(6):653–60. doi:10.1002/bjs.9484.CrossRefPubMed Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. The British Journal of Surgery. 2014;101(6):653–60. doi:10.​1002/​bjs.​9484.CrossRefPubMed
25.
Zurück zum Zitat Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y et al. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Annals of Surgical Oncology. 2014;21(1):213–9. doi:10.1245/s10434-013-3055-x.CrossRefPubMed Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y et al. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Annals of Surgical Oncology. 2014;21(1):213–9. doi:10.​1245/​s10434-013-3055-x.CrossRefPubMed
26.
Zurück zum Zitat Iwasaki Y, Sasako M, Yamamoto S, Nakamura K, Sano T, Katai H et al. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). Journal of Surgical Oncology. 2013;107(7):741–5. doi:10.1002/jso.23301.CrossRefPubMed Iwasaki Y, Sasako M, Yamamoto S, Nakamura K, Sano T, Katai H et al. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). Journal of Surgical Oncology. 2013;107(7):741–5. doi:10.​1002/​jso.​23301.CrossRefPubMed
27.
Zurück zum Zitat Leong T, Smithers BM, Michael M, Gebski V, Boussioutas A, Miller D et al. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer. 2015;15:532. doi: 10.1186/s12885-015-1529-x.CrossRefPubMedPubMedCentral Leong T, Smithers BM, Michael M, Gebski V, Boussioutas A, Miller D et al. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer. 2015;15:532. doi: 10.​1186/​s12885-015-1529-x.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D et al. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. Annals of Surgical Oncology. 2017. doi:10.1245/s10434-017-5830-6. Leong T, Smithers BM, Haustermans K, Michael M, Gebski V, Miller D et al. TOPGEAR: a randomized, phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG. Annals of Surgical Oncology. 2017. doi:10.​1245/​s10434-017-5830-6.
29.
Zurück zum Zitat Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual 8th edition. New York: Springer; 2017. Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual 8th edition. New York: Springer; 2017.
Metadaten
Titel
Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer
verfasst von
Naruhiko Ikoma
Mariela Blum
Jeannelyn S. Estrella
Xuemei Wang
Keith F. Fournier
Paul F. Mansfield
Jaffer A. Ajani
Brian D. Badgwell
Publikationsdatum
17.08.2017
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 10/2017
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-017-3539-2

Weitere Artikel der Ausgabe 10/2017

Journal of Gastrointestinal Surgery 10/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.